Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Clinical Trial

Official title:

Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02588456
• Other study ID #: UPCC 31415, 822967
• Status: Terminated
• Phase: Phase 1
• Start date: October 2015
• Est. completion date: September 2017

Study information

• Verified date: January 2018
• Source: University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART22" cells) administered in split fractions, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: September 2017
• Est. primary completion date: September 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent form must be obtained prior to any research procedure.

2. Relapsed or refractory B-cell ALL:

a. 1st or greater BM relapse OR b. Any marrow relapse after allogeneic HSCT and > 100 days from transplant OR c. For patients with refractory disease: i. < 60 years old that have not achieved a CR after > 2 or more chemotherapy regimens ii. >60 years old that have not achieved a CR after 1 prior chemotherapy regimen d. Patients with Ph+ ALL are eligible if they are intolerant to or have failed tyrosine kinase inhibitor therapy.

e. Patients with CNS3 disease will be eligible if CNS disease is responsive to therapy.

3. Documentation of CD22 expression on malignant cells at relapse.

4. Adequate organ function defined as:

1. Creatinine < 1.6 mg/dl

2. ALT/AST < 3x upper limit of normal range

3. Direct bilirubin <2.0 mg/dl

4. Must have a minimum level of pulmonary reserve defined as = Grade 1 dyspnea, pulse oxygen > 92% on room air, and DLCO > 40% (corrected for anemia)

5. Left Ventricle Ejection Fraction (LVEF) = 40% confirmed by ECHO/MUGA

5. Evidence of disease by standard morphologic or by MRD criteria.

6. Male or female age = 18 years.

7. ECOG Performance Status that is either 0 or 1.

8. No contraindications for leukapheresis.

9. Subjects of reproductive potential must agree to use acceptable birth control methods.

Exclusion Criteria:

1. Active hepatitis B or active hepatitis C.

2. HIV Infection.

3. Class III/IV cardiovascular disability according to the New York Heart Association Classification.

4. Subjects with clinically apparent arrhythmia or arrhythmias who are not stable on medical management within two weeks of enrollment.

5. Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy.

6. Concurrent use of systemic steroids or immunosuppressant medications. Recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary. For additional details regarding use of steroid and immunosuppressant medications.

7. CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity.

8. Pregnant or nursing (lactating) women.

9. Receipt of a prior investigational study agent within 4 weeks prior to enrollment. *Note- patients who have received anti-CD19 CART cells (e.g. CART19/CTL019) on an investigational study where cell infusion occurred greater than 4 weeks before the screening visit are NOT excluded.

10. Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system.

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Intervention

Biological:
• CART22 cells
CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.

Locations

Country	Name	City	State
United States	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Adverse Events		3 years